Trials
Search / Trial NCT05643690

Urine Sample Collection for Validation of the AnchorDx UriFind™ Bladder Cancer Assay

Launched by ANCHORDX MEDICAL CO. LTD. US · Dec 6, 2022

Trial Information

Current as of February 05, 2025

Suspended

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Clinical Validation Group:
  • 1. 55 years or older, gender is not limited
  • 2. Suspected of bladder cancer and are scheduled for bladder biopsy or trans-uretheral resection of bladder tumor (TUBRT)
  • 3. Can receive standard of care, including urine cytology, cystoscopy, or surgery for bladder cancer diagnosis
  • 4. Can provide at least of 75 ml of urine (prior to cystoscopy or surgery)
  • Exclusion Criteria:
  • 1. History of urinary cancer
  • 2. Neoadjuvant therapy

Trial Officials

Jianbing Fan, Ph.D

Study Director

AnchorDx Medical Co., Ltd.

About Anchordx Medical Co. Ltd. Us

Anchordx Medical Co., Ltd. US is a pioneering organization dedicated to advancing healthcare through innovative diagnostic solutions and clinical research. With a strong focus on precision medicine, the company develops cutting-edge technologies that enhance disease detection and patient management. Anchordx Medical is committed to conducting rigorous clinical trials that adhere to the highest ethical standards, aiming to improve patient outcomes and contribute to the scientific community. Through collaboration with healthcare professionals and researchers, the company strives to bring transformative medical advancements to market, ultimately enhancing the quality of care for patients worldwide.

Locations

Little Rock, Arkansas, United States

Meridian, Idaho, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials